1. Home
  2. GRMLW vs ADAMH Comparison

GRMLW vs ADAMH Comparison

Compare GRMLW & ADAMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GRMLW

Greenland Mines Ltd Warrant

N/A

Current Price

$0.28

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

ADAMH

Adamas Trust Inc. 9.875% Senior Notes Due 2030

HOLD

Current Price

$25.79

Market Cap

0.0

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRMLW
ADAMH
Founded
N/A
N/A
Country
United States
United States
Employees
5
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
GRMLW
ADAMH
Price
$0.28
$25.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.9K
12.1K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$24.49
52 Week High
$0.38
$25.99

Technical Indicators

Market Signals
Indicator
GRMLW
ADAMH
Relative Strength Index (RSI) 43.89 59.35
Support Level N/A $25.43
Resistance Level $0.38 $25.81
Average True Range (ATR) 0.07 0.11
MACD -0.01 0.00
Stochastic Oscillator 0.00 88.00

Price Performance

Historical Comparison
GRMLW
ADAMH

About GRMLW Greenland Mines Ltd Warrant

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: